JPRN-UMIN000030593招募中未知
Clinical Phase I / II trial of weekly docetaxel therapy in conjunction with radiation in case of FP therapy refractory cases in esophageal cancer - Clinical Phase I / II trial of weekly docetaxel therapy in conjunction with radiation in case of FP therapy refractory cases in esophageal cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients receiving transfusions, blood products and hematopoietic factor preparations such as G-CSF within 14 days before registration 2) Cases with infections or diseases requiring systemic administration of antibiotics, antifungal agents 3) Cases with complications as shown below Control poor hypertension, diabetes Severe lung disease (interstitial pneumonia, pulmonary fibrosis, advanced emphysema, etc.) Liver failure Gastrointestinal bleeding that requires treatment 4) Patients with marked electrocardiogram abnormality or cases with clinically problematic heart disease Cases with congestive heart failure, symptomatic coronary artery disease, poorly controlled arrhythmia, a history of myocardial infarction that developed within the last 12 months, etc 5) Cases with psychiatric disorder judged by the investigator or test sharing doctor to have acquired consent or adversely affect test performance Control malfunctioning epileptic seizures, central nervous system disorders, etc. 6) Cases with moderate or more ascites (above the pelvic cavity) or with large pleural effusions 7) Cases with brain metastasis or suspected brain metastasis from clinical symptoms 8) Cases with extensive bone metastases 9) Cases with active duplicated cancers 10) HIV antibody positive cases 11) Patients who received treatment with another study drug within 4 weeks before registration of this study or participate in other clinical trials (incidental study of this study "Esophageal cancer chemical radiation by genetic analysis Clinical research on susceptibility of therapy and prediction of side effects "excluding) 12) Cases judged unsuitable as subjects of the examination by the investigator
研究者
相似试验
已完成
1 期
Phase I/II trial of weekly docetaxel and concomitant radiotherapy for unresectable esophageal squamous cell carcinoma after induction chemothrapynresectable esophageal squamous cell carcinoma after induction chemotherapyJPRN-UMIN000004856Gastroenterologic surgery, Kanazawa university44
进行中（未招募）
2 期
A phase II trial of weekly docetaxel (Taxotere) for patients with relapsed ovarian cancer who have previously received paclitaxelRelapsed ovarian cancerCancer - Ovarian and primary peritonealACTRN12605000390684HMRC Clinical Trial Centre c/- Univ of Sydney60
已完成
2 期
Phase II study of docetaxel monotherapy plus primary prophylaxis with pegfilgrastim for pre-treated locally advanced or metastatic non-small cell lung cancer.JPRN-UMIN000016383Dept. Respiratory Medicine, Osaka Police Hopital31
已完成
1 期
A phase I trial of 100mg/m2 docetaxel in advanced or recurrent breast cancer patients.advanced or recurrent breast cancer patients.JPRN-UMIN000015820Okayama University Hospital Center for Innovative Clinical Medicine6
已完成
不适用
A phase II trial of docetaxel in the treatment of elderly patients (aged 70 or over) with non-small cell lung cancerCancerISRCTN27242710Maidstone and Tunbridge Wells NHS Trust (UK)55